The cluster is small in absolute dollars but directionally consistent — 6 funds all adding while 3 trimming negligibly. D.E. Shaw's quant models finding XERS attractive is a positive signal, but the $2.1M net buy on a micro-cap biotech with recent insider selling suggests moderate conviction, not transformative. Monitor for pipeline catalysts (FDA decisions, trial readouts) that could explain the shared thesis and provide a near-term trigger.
Executive Summary
Six institutional buyers accumulated $3.5M in XERS shares during 2024-Q3, led by quant hedge fund D.E. Shaw which added $1.6M to its position (now $2.8M), while three asset managers trimmed $82K. The buying is concentrated and net-positive at $2.1M, but absolute dollar amounts are micro-cap scale. Insider selling of $311K over the prior 30 days adds a cautionary note.
Key Financial Metrics
Institutional Positions
Net institutional flow: $2.1M
▲ Buyers (6)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| D.E. Shaw | ADD | +90.1% | $2.8M | $1.6M |
| Legal & General Group | DOUBLED | +1317.9% | $601.0K | $567.0K |
| Corient Private Wealth | ADD | +53.7% | $72.0K | $35.0K |
▼ Sellers (3)
| Institution | Action | Change | Prev Value | Value Δ |
|---|---|---|---|---|
| Mariner | TRIM | -54.8% | $151.0K | -$64.5K |
| Metlife Investment Management | TRIM | -28.4% | $186.0K | -$17.2K |
| Lazard Asset Management | TRIM | -40.5% | $1.0K | -$353.00 |
Key Facts
- 6 buyers accumulated $3.5M vs 3 sellers trimmed $82K — net $2.1M into XERS in Q3 2024
- D.E. Shaw (quant/hedge fund) was the dominant buyer: added 467K shares, growing position to $2.8M from $1.2M
- Legal & General Group nearly 14x'd its position (+1318%) to $601K, Corient Private Wealth added 54% to $72K
- Sellers were small-scale trims: Mariner ($65K cut), Metlife ($17K cut), Lazard ($353 cut)
- Prior 30-day insider activity: 3 sells totaling $311K — mild bearish signal at the security level
- Analyst consensus is 85% bullish (5 Strong Buy, 6 Buy, 2 Hold) on this clinical-stage biotech
Financial Impact
Net institutional inflow of approximately $2.1M into XERS stock during Q3 2024, with D.E. Shaw and Legal & General accounting for 93% of buying. Total disclosed institutional positions now ~$3.5M across 6 funds.
Risk Factors
- Absolute dollar amounts are tiny ($3.5M aggregate) — may reflect routine rebalancing, not conviction
- 13F data is 45+ days stale; these positions may have been fully unwound since quarter-end
- Recent insider selling ($311K/30d) conflicts with institutional buying signal
- XERS is a clinical-stage biotech with no approved revenue — binary pipeline risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-XERS-2024-Q3 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | 8-K | $7.71 $7.78 | ▲ +0.91% | ▲ +1.56% | — |
Sep 1, 2026 4w ago | Insider Cluster | $8.58 $7.67 | ▼ −10.61% | ▼ −9.65% | — |
Aug 6, 2026 8w ago | 8-K | $7.36 $8.33 | ▲ +13.18% | ▲ +11.97% | — |
Aug 4, 2026 8w ago | Insider Cluster | $8.19 $8.39 | ▲ +2.44% | ▲ +2.54% | — |
Jul 7, 2026 12w ago | Insider Cluster | $8.94 $8.28 | ▲ +7.38% | ▲ +7.93% | — |
Jul 2, 2026 13w ago | 3 | $8.28 $8.62 | ▲ +4.11% | ▲ +3.18% | — |
Jul 2, 2026 13w ago | Insider Cluster | $8.28 $8.62 | ▲ +4.11% | ▲ +3.18% | — |
Jun 30, 2026 13w ago | 8-K | $8.00 $8.94 | ▲ +11.75% | ▲ +11.49% | — |
Jun 12, 2026 16w ago | Institutional Cluster | $6.79 $6.95 | ▲ +2.36% | ▲ +1.68% | — |
Jun 5, 2026 17w ago | Insider Cluster | $6.24 $6.88 | ▲ +10.26% | ▲ +8.14% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access